Shire Sues Impax Again Over New Adderall ANDAs

Law360, New York (January 16, 2005, 12:00 AM EST) -- U.K. drug maker Shire Pharmaceuticals has filed a second lawsuit against U.S. generics maker Impax Labs based on an abbreviated new drug application for another dosage of best-selling attention-deficit drug Adderall XL.

Shire, which has already sued Impax over its Paragraph IV notice letter for a 30 mg generic version of Adderall XR, has filed a second complaint based on an additional Paragraph IV notice letter for a generic version of the 5 mg, 10 mg, 15 mg, 20 mg and 25 mg strengths of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.